Previous 10 | Next 10 |
2024-02-19 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle - - Additional Data from ACHIEVE and DELIVER Trials Expected in the Seco...
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to ...
2024-01-26 14:42:19 ET More on Dyne Therapeutics Assessing Dyne Therapeutics' Muscular Dystrophy Data: Early Promise, Caution Needed Dyne Therapeutics prices stock offering to raise $300.1 million Biggest stock movers today: Crypto stocks, SoFi Technologies, Bloomin'...
2024-01-18 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-12 16:40:04 ET Gainers: Outset Medical ( OM ) +11% . Kandi Technologies Group ( KNDI ) +7% . Dyne Therapeutics ( DYN ) +5% . Revance Therapeutics ( RVNC ) +4% . NovoCure Limited ( NVCR ) +3% . Losers: Gritstone...
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously ann...
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and ...
2024-01-05 01:10:35 ET More on Dyne Therapeutics Assessing Dyne Therapeutics' Muscular Dystrophy Data: Early Promise, Caution Needed Dyne surges on positive Phase 1/2 data for muscle disorder candidates Seeking Alpha’s Quant Rating on Dyne Therapeutics ...
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten pu...
News, Short Squeeze, Breakout and More Instantly...
2024-04-30 06:00:04 ET Michael Ulz from Morgan Stanley issued a price target of $40.00 for DYN on 2024-04-30 04:50:00. The adjusted price target was set to $40.00. At the time of the announcement, DYN was trading at $25.46. The overall price target consensus is at $20.50...
2024-04-20 23:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an induceme...